**CURRICULUM VITAE**

**Name:** Mark Anthony Perazella, MD, MS  
**School:** Yale University School of Medicine  
**Education:**  
- B.S. University of Connecticut, 1981  
- M.S. Systemic & Evolutionary Biology, University of Connecticut, 1983  
- M.D. New York Medical College, 1988  

**Career/Academic Appointments:**  
| Year          | Position Description                                      | Institution and Location                             |
|---------------|-----------------------------------------------------------|------------------------------------------------------|
| 1988-1989     | Intern, Internal Medicine, Yale Primary Care Program, St. Mary's Hospital, Waterbury & New Haven, CT |
| 1989-1991     | Junior & Senior Resident, Internal Medicine, Yale Primary Care Program, St. Mary's Hospital, Waterbury & New Haven, CT |
| 1991-1993     | Fellow, Nephrology, Yale University School of Medicine, New Haven, CT |
| 1994-1995     | Clinical Instructor in Medicine, Yale University School of Medicine, New Haven, CT |
| 1995-1998     | Assistant Professor in Medicine, Yale University School of Medicine, New Haven, CT |
| 1998-2010     | Associate Professor of Medicine, Yale University School of Medicine, New Haven, CT |
| 2010-present  | Professor of Medicine, Yale University School of Medicine, New Haven, CT |

**Administrative Positions:**  
| Year          | Position Description                                      | Institution and Location                             |
|---------------|-----------------------------------------------------------|------------------------------------------------------|
| 1993-1995     | Assistant Program Director, Yale Primary Care Residency Program, St. Mary's Hospital, Waterbury, CT |
| 1993-1995     | Director Hypertension Clinic, Yale Primary Care Residency Program, St. Mary's Hospital, Waterbury, CT |
| 1995-2003     | Associate Medical Director of Dialysis Yale-DaVita Dialysis Center, New Haven, CT |
| 1995-present  | Director, Acute Dialysis Services Yale-New Haven Hospital-Davita Dialysis Center, New Haven, CT |
| 2003-2014     | Training Program Director, Nephrology Fellowship Program, Yale University School of Medicine, New Haven, CT |
| 2005-present  | Co-Director, CPC Conference, Yale University School of Medicine, Section of Nephrology, |
New Haven, CT

2005-2009
Scientific Director, Internal Medicine Residency training Program, St. Mary’s Hospital, Waterbury, CT (Yale Affiliate)

2008-present
Medical Director, Yale Physician Associate Program, Yale University School of Medicine New Haven, CT

2009-present
Medical Director, Erythropoiesis stimulating agent Clinic, VAMC, West Haven, CT

2009-present
Co-Director, Statewide Renal Biopsy Conference, Yale University School of Medicine, New Haven, CT

2014-present
Clinical Director, Yale University Nephrology Site, TRENAL Program, New Haven, CT

2015-present
Medical Director, CRRT Program, VAMC, West Haven, CT

2014-present
Chair, Academic Affairs Committee, Yale Physician Associate Program, New Haven, CT

2014-present
Education Co-Director, ASN Board Review and Update Course

2016-present
Medical Director, Yale Physician Assistant Online Program, Yale University School of Medicine New Haven, CT

Board Certification:

American Board of Internal Medicine, Internal Med, 1991, 2001
American Board of Internal Medicine, Nephrology, 1994, 2004, 2014

Professional Honors & Recognition:

A) International/National/Regional

2013: Leading Physicians of the World, Top Nephrologist
2009: Lifetime Achievement Award, Sacred Heart High School, Waterbury CT.
2007: Top Physician Consumers’ Research Council of America
2000-2005: AMA Physician’s Recognition Award for Continuing Medical Education
1995-2000: AMA Physician’s Recognition Award for Continuing Medical Education
1991: ACP Research Competition, Finalist: Paper Division National ACP Meeting, New Orleans, LA

B) University

2014: Leadership in Education Award, Yale University School of Medicine Nephrology Fellowship
2012: **Commitment to Education Award**, Yale University School of Medicine Nephrology Fellowship

2005: **Department of Medicine Achievement Award in Education**, Yale University School of Medicine

1995: **Teacher of the Year**, Yale Primary Care Internal Medicine Program

**Lectures, Courses:**

2020: **American Society of Nephrology BRCU (Webinar):** Session Moderator “Glomerular and Vascular Disorders”

2019: **American Society of Nephrology BRCU (Webinar):** “Acute Tubulointerstitial Nephritis”

2020: **NKF Spring Clinical Meeting, New Orleans (Virtual):** “Urine Microscopy Cases”

2020: **NKF Spring Clinical Meeting, New Orleans (Virtual):** Session Chair “Urine Microscopy for the Clinical Nephrologist”

2020: **NKF Spring Clinical Meeting, New Orleans (Virtual):** Session Chair “Hot Topics in Onco-Nephrology”

2020: **NKF Spring Clinical Meeting, New Orleans (Virtual):** Session Chair “Acute interstitial nephritis: What’s new?”

2020: **NKF Spring Clinical Meeting, New Orleans (Virtual):** Pre-Course Director “Diagnostic Testing in Nephrology: Case-Based Discussions”

2020: **Northwell University Visiting Professor (Medical Grand Rounds):** “Renal dystopia in the MICU”

2020: **Northwell University (Nephrology Conference):** “AKI for the Onco-Nephrologist”

2019: **Ohio State University/Wexner Medical Center Visiting Professor (Medical Grand Rounds):** “Hospital-acquired AKI: Bugs, Drugs or something else?”

2019: **Ohio State University/Wexner Medical Center Visiting Professor (Nephrology Grand Rounds):** “Onco-Nephrology and AKI: Cancer and its therapy”
| Year | Event                                                                                     |
|------|-------------------------------------------------------------------------------------------|
| 2019 | **American Society of Nephrology Kidney Week:** Moderator for the session “Nephrology Quiz and Questionnaire” |
| 2019 | **American Society of Nephrology Kidney Week:** “Acute Kidney Injury in Cancer”             |
| 2019 | **Porto Clinical Nephrology Update Conference, Porto, Portugal:** Chair for session “Cases in drug-induced AKI” |
| 2019 | **Porto Clinical Nephrology Update Conference, Porto, Portugal:** “Update on drug-induced AKI” |
| 2019 | **Mayo Clinic Visiting Professor:** “AKI in the MICU: Drugs, Bugs or other Thugs?”         |
| 2019 | **Mayo Clinic Visiting Professor:** “Drug-induced AKI: Tubules under attack”               |
| 2019 | **American Society of Nephrology BRCU:** “Imaging in Nephrology”                          |
| 2019 | **American Society of Nephrology BRCU:** “Acid-Base and Electrolyte Board Questions”      |
| 2019 | **American Society of Nephrology BRCU:** “Onco-Nephrology: Board cases”                    |
| 2019 | **American Society of Nephrology BRCU:** “Urinalysis/Urine microscopy: A case-based approach” |
| 2019 | **American Society of Nephrology BRCU:** “Nephrotoxins for the Boards”                    |
| 2019 | **American Society of Nephrology BRCU:** “Acute and chronic interstitial diseases”        |
| 2019 | **NKF Spring Clinical Meeting, Boston, MA:** Session Chair “Physician burnout”             |
| 2019 | **NKF Spring Clinical Meeting, Boston, MA:** Session Chair “SGLT-2 inhibitor”             |
| 2019 | **NKF Spring Clinical Meeting, Boston, MA:** “Drug-induced acute kidney injury”           |
| 2019 | **NKF Spring Clinical Meeting, Boston, MA:** “Cancer and acute kidney injury”             |
| 2019 | **Fifth International Renal Meeting with Mayo Clinic in Sardinia:** “Update on anti-cancer drugs and kidney injury” |
2018: Kidney Disease Improving Global Outcomes (Milan, Italy): “Onco-Nephrology: Perspectives from Nephrology”

2018: American Society of Nephrology Annual Meeting: “Clinical cases”

2018: American Society of Nephrology Annual Meeting: “Kidney toxicology phenotypes associated with Cancer Drugs and Biologics”

2018: American Society of Nephrology Annual Meeting: Moderator of the session “Nephrology Quiz and Questionnaire”

2018: Charite-Universitatsmediz (Berlin, Germany): “Cancer therapy and kidney disease”

2018: Charite-Universitatsmediz (Berlin, Germany): AKI in the hospitalized patient”

2018: NCCR Kidney.CH Summer School 2018 (U of Zurich): “Drug-induced kidney injury”

2018: University of Degli Studi di Milano (Milan, Italy): “Novel anti-cancer agents and the kidney”

2018: IRCCS Istituti Clinici Scientifici Maugeri (Pavia, Italy): “Cancer drug nephrotoxicity: an update”

2018: American Society of Nephrology BRCU: “Imaging in Nephrology”

2018: American Society of Nephrology BRCU: “Acid-Base and Electrolyte Board Questions”

2018: American Society of Nephrology BRCU: “Onco-Nephrology: Board cases”

2018: American Society of Nephrology BRCU: “Urinalysis/Urine microscopy: A case-based approach”

2018: American Society of Nephrology BRCU: “Nephrotoxins for the Boards”

2018: American Society of Nephrology BRCU: “Acute and chronic interstitial diseases”

2018: Beth Israel Deaconess Medical Center Nephrology Grand Rounds: “Cancer Therapy and Kidney Disease”

2018: NKF Spring Clinical Meeting, Austin, Texas: “PPIs:
Are they inducers of Kidney Disease?

2018: **NKF Spring Clinical Meeting, Austin, Texas: “AKI and Cancer Therapy”**

2018: **Internal Medicine Grand Rounds, Rutgers University/Robert Wood Johnson: “Update in Onco-Nephrology for the Internist”**

2018: **Baylor Medical Conference, Baylor University: Onco-Nephrology: “Cancer and Kidney Disease”**

2018: **Austin Lecture Medical Grand Rounds, Baylor University: “AKI in a complicated ICU patient with sepsis”**

2018: **Internal Medicine Grand Rounds, Waterbury Hospital: “Update in Onco-Nephrology”**

2017: **Onco-Nephrology International Conference, Naples, Italy: “Why a conference on onco-nephrology?”**

2017: **Memorial Sloan Kettering Nephro-Oncology Symposium: “Immunotherapy-associated nephrotoxicity”**

2017: **American Society of Nephrology Annual Meeting: “Acute kidney injury and cancer”**

2017: **American Society of Nephrology Annual Meeting: “Cholestasis and AKI: An under-recognized clinical entity?”**

2017: **American Society of Nephrology Annual Meeting: Moderator for the session “Nephrology Quiz and Questionnaire”**

2017: **12th Nephrology and Transplantation Update (Emirates Medical Association Nephrology): “Drug-induced acute kidney injury”**

2017: **12th Nephrology and Transplantation Update (Emirates Medical Association Nephrology): “Approach to diagnosing acute interstitial nephritis”**

2017: **American Society of Nephrology BRCU: “Imaging in Nephrology”**

2017: **American Society of Nephrology BRCU: “Diabetic nephropathy cases”**

2017: **American Society of Nephrology BRCU: “Acid-Base and Electrolyte Board Questions”**
2017: American Society of Nephrology BRCU: “Onco-Nephrology: Board cases”
2017: American Society of Nephrology BRCU: “Urinalysis/Urine microscopy: A case-based approach”
2017: American Society of Nephrology BRCU: “Nephrotoxins for the Boards”
2017: American Society of Nephrology BRCU: “Acute and chronic interstitial diseases”
2017: University of Pennsylvania- Updates in Kidney Transplantation and Onco-Nephrology: “Anti-cancer drug nephrotoxicity”
2017: International Society of Nephrology/World Congress of Nephrology Meeting: Co-Chair of “Plenary Session on Genetics of Kidney Disease”
2017: International Society of Nephrology/World Congress of Nephrology Meeting: “Update on the adverse renal effects of anti-cancer agents”
2017: Yale Nephrology Pathophysiology Noon Conference: “Acute interstitial nephritis”
2016: American Society of Nephrology Annual Meeting: Moderator of the session “Nephrology Quiz and Questionnaire”
2016: American Society of Nephrology Annual Meeting: Moderator of the session “Tubulointerstitial Disease: Double Trouble in the Kidney”
2016: American Society of Nephrology Annual Meeting: “Kidney toxicology phenotypes associated with Cancer Drugs and Biologics”
2016: American Society of Nephrology Annual Meeting: “Acute kidney injury and cancer”
2016: MD Anderson Cancer Center Onco-Nephrology Symposium: “Chemotherapy-induced Nephrotoxicities”
2016: Winthrop University Hospital Nephrology Grand Rounds: “AKI in the critically ill ICU patient”
2016: Bridgeport Hospital Medical Grand Rounds: “Approach to AKI in hospitalized patients”
2016: **American Society of Nephrology BRCU:** “Imaging in Nephrology”

2016: **American Society of Nephrology BRCU:** “Diabetic nephropathy cases”

2016: **American Society of Nephrology BRCU:** “Acid-Base and Electrolyte Board Questions”

2016: **American Society of Nephrology BRCU:** “Onco-Nephrology: Board cases”

2016: **American Society of Nephrology BRCU:** “Urinalysis/Urine microscopy: A case-based approach”

2016: **American Society of Nephrology BRCU:** “Nephrotoxins for the Boards”

2016: **American Society of Nephrology BRCU:** “Acute and chronic interstitial diseases”

2016: **University of Massachusetts Nephrology Grand Rounds:** “Clinical approach to the diagnosis and treatment of acute interstitial nephritis”

2016: **Advocate Christ Medical Center Medical Grand Rounds:** “Evaluation of AKI in ICU patients”

2016: **Montefiore/Albert Einstein Nephrology Grand Rounds:** “Approach to AKI in hospitalized patients”

2015: **University Medical Center of Princeton Medical Grand Rounds:** “Evaluating AKI in the 21st Century”

2015: **American Society of Nephrology Annual Meeting:** “Approach to the patient with suspected AIN”

2015: **American Society of Nephrology Annual Meeting:** Moderator of the session “Evaluating AKI in the 21st Century”

2015: **American Society of Nephrology Annual Meeting:** Moderator of the session “Nephrology Quiz and Questionnaire”

2015: **North Shore LIJ Onco-Nephrology: Cancer, Chemotherapy and the Kidney:** “Chemotherapy-induced Nephrotoxicities”

2015: **Joseph L. Renda Memorial Lecture, Yale Nephrology Grand Rounds:** “Acute interstitial nephritis”
2015: **TRENAL Program, Erlangen, Germany, Erlangen Nephrology Department Renal Conference:** “Case-based approach to Urine Microscopy”

2015: **American Society of Nephrology BRCU:** “Acid-Base and Electrolyte Board Questions”

2015: **American Society of Nephrology BRCU:** “Onco-Nephrology: Board cases”

2015: **American Society of Nephrology BRCU:** “Urinalysis/Urine microscopy: A case-based approach”

2015: **American Society of Nephrology BRCU:** “Nephrotoxins for the Boards”

2015: **American Society of Nephrology BRCU:** “Acute and chronic interstitial diseases”

2015: **Toronto Onco-Nephrology Interest Group:** “Nephrotoxicity in the Onco-Nephrology World: A growing list of drugs”

2015: **Research Day 2015, St. Mary’s Hospital:** “An academic career in Medicine/Nephrology: The prequel.”

2015: **Rutgers University/Robert Wood Johnson Medical Grand Rounds:** “AKI in the septic ICU patient: ATN or something else?”

2014: **American Society of Nephrology Annual Meeting:** Moderator of the session “Doctor, your patient is getting worse! Are you sure the drug dose is right?”

2014: **American Society of Nephrology Annual Meeting:** Moderator of the session “Extracorporeal therapies for intoxications and drug overdoses”

2014: **American Society of Nephrology Annual Meeting:** Moderator of the session “Nephrology Quiz and Questionnaire”

2014: **Weill Cornell Medical Center Nephrology Grand Rounds:** Visiting Professor “AKI in the ICU: another case of ATN?”

2014: **Italian Congress of Nephrology:** “The development of onco-nephrology in the USA: past, present, and future”
| Year | Event/Conference | Topic/Program |
|------|------------------|---------------|
| 2014 | University of Buffalo/Division of Nephrology | Drug-induced AIN: Diagnosis and treatment |
| 2014 | ASN Board Review Course and Update | “Urine microscopy cases” |
| 2014 | Henry Ford Hospital Nephrology Grand Rounds | Hospital-acquired AKI: What is the diagnosis? |
| 2014 | Henry Ford Hospital Nephrology Fellow Rounds | Utility of urine microscopy in kidney disease: case-based discussion |
| 2014 | National Kidney Foundation Annual Clinical Meeting | “AKI Associated with Anti-Microbial Use” |
| 2014 | National Kidney Foundation Annual Clinical Meeting | “Acid–Base Abnormalities and Toxic Ingestions: A Case–Based Discussion” |
| 2014 | Stamford Hospital Medical Grand Rounds-Paul Dalgin Lecture | “Drug-induced kidney injury: an update” |
| 2014 | Yale Primary Care Program/Waterbury Hospital Medical Grand Rounds-Renda Lecture | “Utility of urine microscopy in hospital-acquired AKI” |
| 2014 | Iranian Congress of Nephrology, Dialysis and Transplantation | “Intoxications and overdose for the nephrologist” |
| 2014 | Iranian Congress of Nephrology, Dialysis and Transplantation | “Update on diagnosis and management of drug-induced AIN” |
| 2014 | Iranian Congress of Nephrology, Dialysis and Transplantation | “Urine microscopy in AKI: Case-based discussion” |
| 2013 | American Society of Nephrology Annual Meeting | Moderator of the session “Nephrology Quiz and Questionnaire” |
| 2013 | American Society of Nephrology Annual Meeting | Moderator of the session “Designer drugs, contaminants, and other drugs of abuse” |
| 2013 | American Society of Nephrology Annual Meeting | Moderator of the session “Management of Uremia” |
| 2013 | American Society of Nephrology Annual Meeting | “NephSAP Cancer and the Kidney Board Review” |
2013: American Society of Nephrology Annual Meeting: “Chemotherapeutic agents and the kidney”

2013: National Kidney Foundation Annual Clinical Meeting: “Chemotherapeutic agents and the kidney”

2013: National Kidney Foundation Annual Clinical Meeting: “Basics of urine microscopy”

2013: National Kidney Foundation Annual Clinical Meeting: “Urine microscopy: a case-based approach”

2012: American Society of Nephrology Annual Meeting: “Chemotherapeutic agents and the kidney”

2012: American Society of Nephrology Annual Meeting: “Use of a urine microscopy scoring system in the diagnosis and prognosis of ATN”

2012: American Society of Nephrology Annual Meeting: “Novel nephrotoxins associated with renal tubular injury”

2012: Magen Marcus Yale Hospitalist Symposium: “Update on hospital-acquired AKI”

2012: National Kidney Foundation Annual Clinical Meeting: “Urine microscopy”

2012: National Kidney Foundation Annual Clinical Meeting: “Urine microscopy: a case-based approach”

2011: Yale University Medical Grand Rounds: “Utility of traditional biomarkers in hospital-acquired AKI: what is old is new again”

2011: American Society of Nephrology Annual Meeting: “Chemotherapeutic agents and the kidney”

2011: American Society of Nephrology Annual Meeting: Moderator of the session “AKI in the ICU”

2011: National Kidney Foundation Annual Clinical Meeting: “Gadolinium contrast, kidney disease and NSF”

2010: American Society of Nephrology Annual Meeting: “Nephrotoxicity of pharmaceuticals”

2010: Weill Cornell Medical Center Nephrology Grand Rounds: Visiting Professor “Nephrotoxicity in a drug crazed world”
2010: American College of Physicians Annual Internal Medicine Meeting: Meet the Professor “Problems and Controversies in Imaging in Nephrology - Enhancing safety in imaging patients with kidney disease”

2010: American College of Physicians Annual Internal Medicine Meeting: Lunch with the Professor “Discussion about imaging options in patients with kidney disease”

2009: American Society of Nephrology Annual Meeting: Moderator of the session “Hepatitis C and Renal Disease”

2009: American Society of Nephrology Annual Meeting: Moderator of the session “Appealing to the Base: Nephrologists and Intensivists view of Acidosis”

2009: Hartford Hospital Medical Grand Rounds: Nephrogenic Systemic Fibrosis: What the Internist needs to know”

2008: American Society of Nephrology Annual Meeting: “Current status of gadolinium as a nephrotoxin and cause of Nephrogenic Systemic Fibrosis”

2008: National Kidney Foundation Annual Clinical Meeting: “Update on NSF: Lessons learned from the NSF Registry”

2008: New York Society of Nephrology: “Update on drug-induced Kidney Disease”

2008: University of Virginia Medical Grand Rounds: Visiting Professor “Update on Nephrogenic Systemic Fibrosis”

2008: University of Medicine and Dentistry in New Jersey (UMDNJ): “Drug-induced Kidney Disease”

2007: American Society of Nephrology Annual Meeting: “Nephrogenic Systemic Fibrosis: What we currently know about this new disease entity”

2007: American Society of Nephrology Annual Meeting: Moderator of the session “Adsorbents in Dialysis”

2007: American Society of Nephrology Annual Meeting: Moderator of the session “New management strategies & treatment of glomerulonephritis”

2006: American Society of Nephrology Annual Meeting: “Proton pump inhibitors and the kidney: Critical review”
2006: International Society of Nephrology/World Congress of Nephrology Meeting: “Acute interstitial nephritis”

2006: Johns Hopkins University Renal Grand Rounds: Visiting Professor, “Nephrogenic Systemic Fibrosis”

2006: Winthrop University Hospital Medical Grand Rounds: “Drug-induced Kidney Disease”

2006: Brown University Renal Grand Rounds: “VEGF and the Kidney: Hypertension and Kidney Disease”

2005: American Society of Nephrology Annual Meeting: “Vulnerability of the Kidney to Nephrotoxins”

2004: UT Southwestern Renal Grand Rounds: “Evaluation and treatment of Dialysis-associated hypotension”

2003: Brown University Renal Grand Rounds: “COX-2 Inhibitors and the Kidney”

2002: Northwestern University Nephrology Research Conference: “Pathophysiology and management of dialysis-associated hypotension”

2002: SUNY Downstate (Brooklyn): “AIDS & the Kidney” Symposium “ARF in HIV-infected patients: Inevitable or preventable?”

2002: Winthrop University Hospital Renal Grand Rounds: Visiting Professor “COX-2 Inhibitors and the Kidney”

2002: American Academy of Family Practitioners Symposium: “Renal effects of COX-2 Inhibitors in the at-risk patient”

2002: University of Florida Renal Grand Rounds: Visiting Professor “Pathophysiology and treatment of Dialysis-associated Hypotension”

2002: National Kidney Foundation Annual Clinical Meeting: “Treatment of Intradialytic Hypotension”
2002: **American Society of Nephrology/International Society of Nephrology Meeting:** “New therapies for Intradialytic Hypotension”

2002: **American Nephrology Nursing Association National Meeting of Chicago Chapter:** “Evaluation and treatment of Intradialytic Hypotension”

2002: **Postgraduate Institute for Medicine:** Symposium on Clinical Utility of Selective COX-2 Inhibitors “Adverse Renal Effects of NSAIDs”

1999: **University of Massachusetts Nephrology Grand Rounds:** “NSAID nephrotoxicity”

**PROFESSIONAL SERVICE**

**Peer Review Groups/Grant Study Sections**

2017  **Chair, Abstract Committee,** International Society of Nephrology/World Congress of Nephrology

2015  **Chair, Abstract Category,** “Fellows Case Reports Category” American Society of Nephrology Annual Scientific Meeting

2011  **Abstract Reviewer,** “Clinical Nephrology: AKI and CKD Category” American Society of Nephrology Annual Scientific Meeting

2009  **Abstract Reviewer,** “Clinical Nephrology: Electrolyte and Acid–Base Disorders Category” American Society of Nephrology Annual Scientific Meeting

2007  **Abstract Reviewer,** “Clinical Nephrology: Glomerular Disorders Category” American Society of Nephrology Annual Scientific Meeting

2001  **Abstract Reviewer,** “Complications of Dialysis Category”, American Society of Nephrology Annual Scientific Meeting

**Journal Service**

2019–Present  **Deputy Editor,** Kidney360 (ASN Journal)

2018–Present  **Co-Editor-in-Chief,** Journal of Onco-Nephrology

2017–Present  **Editorial Board,** Kidney International Reports

2017–Present  **Editorial Board,** The American Journal of Kidney Diseases

2017–Present  **Editorial Board,** Clinical Journal of American Society of Nephrology

2016–2018  **Associate Editor,** Journal of Onco-Nephrology
2014–Present  **Editorial Board, Journal of Nephrology**
2013–Present  **Section Editor (Acute Kidney Injury), Clinical Nephrology**
2009–Present  **Editorial Board of Neph Ed section, Clinical Nephrology**
2009–Present  **Editorial Board, The Open Toxinology Journal**
2008–Present  **Editorial Board, The Open Urology & Nephrology Journal**
2007–Present  **Associate Editor, Internet Journal of Nephrology**
2006–2017  **Associate Editor, Clinical Journal of American Society of Nephrology**
2006–2017  **Core Curriculum Advisory Board/Editorial Board, The American Journal of Kidney Diseases**
2005–Present  **Editorial Board, The American Journal of Medicine**
2004–2007  **Associate Editor, The American Journal of Kidney Diseases**
2002–2015  **Editorial Board, The American Journal of Medical Sciences**
2001–2008  **Editorial Board, Hospital Physician**
• **Series Editor, Chronic Kidney Disease**
• **Series Editor, Resident Grand Rounds**
1999–2002  **Editorial Board, The American Journal of Kidney Diseases**
1998–Present  **Assistant Editor, Seminars in Dialysis**
• **Series Editor, Fellows Forum in Dialysis**
• **Series Co-editor, Images in Dialysis**

**Professional Organizations**

**American Board of Internal Medicine**

2007–2013  Test Writing Committee Member, ABIM Nephrology Subspecialty Board
1991–Present  ABIM Diplomate

**American Society of Nephrology**

2018–2019  Member of ASN Kidney Week Program Committee
2015–2018  Member of the ASN Board of Advisors
2014–Present  ASN Education Co-Director, Board Review Course and Update (BRCU)
2014–2019  Member of the ASN Education Committee
2013–2018  ASN Chair, Onco-Nephrology Advisory Group
2013–2019  Member of the ASN Postgraduate Education Committee
2008-Present  Elected to ASN Fellowship
2006-2009  Member of Training Program Director
            Executive Committee
1993-Present  ASN Member

American College of Physicians
1997-1999  Officer, Governor's Council, CT Chapter
1996-1998  Chairman, Associates Scientific
            Committee, CT Chapter
1995-Present  Elected to ACP Fellowship
1991-Present  ACP Member

National Kidney Foundation
2019-2020  Chair of National Kidney Foundation
            Spring Clinical Meeting (New Orleans)
2018-2019  Co-Chair of National Kidney Foundation
            Spring Clinical Meeting (Boston)
2009-2016  Member of the NKF KDOQI Education
            Committee
2011-Present  Elected to NKF Fellowship
1993-2000  Member of the NKF Scientific Council

International Society of Nephrology
2017: Chair, ISN/WCN Abstract Committee (Mexico City,
        Mexico)

Kidney Disease Improving Global Outcomes (KDIGO)
2018: Participant in “Onco-Nephrology Controversies
        Conference” (Milan, Italy)

Kidney Disease Improving Global Outcomes (KDIGO)
2019: Participant in “Nomenclature for Kidney Function
        and Disease” (Amsterdam, Netherlands)

Yale University Service

University Committees
2005-2012  Member of the Graduate Medical Education
            Committee, Yale University

Hospital Committees
2009-Present  Member of the Multidisciplinary Contrast
              Committee
2005-2013  Member of the Multidisciplinary
              Peripheral Vascular QA Committee
2004-present  Chair of Multidisciplinary Committee on
              CRRT (CVVH & CVVHDF)
2000-2001  Member of the Credentialing Committee
            for Vascular Procedures

Departmental/Sectional Committees
2014-present  Member of the Nephrology ACGME
              Competency Committee
Mark A Perazella, MD

2004-2014 Chair of the Nephrology ACGME Competency Committee
1997-2000 Member of the Yale Internal Medicine Residency Working Group

Public Service
2002-present Associate of the Cushing/Whitney Medical Library
2001, 2007 Consultant for Consumers Report on Health and Disease

BIBLIOGRAPHY:

1. Peer Reviewed Original Research

Perazella MA, Buller GK: Successful treatment of cystinuria with captopril. Am J Kidney Dis. 1993;21:504-507.

Velazquez H, Perazella MA, Wright F and Ellison D: Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119: 296-301.

Perazella MA, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ: Enalapril treatment of post-transplant erythrocytosis: Efficacy independent of circulating erythropoietin levels. Am J Kidney Dis. 1995;26: 495-500.

Alappan R, Perazella MA, Buller GK: Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996;124: 316-320.

Cruz DN, Perazella MA, Abu-Alfa A, Mahnensmith RL: ACE inhibitor therapy in chronic hemodialysis patients: Any evidence for erythropoietin resistance? Am J Kid Dis. 1996;28: 535-540.

Cruz DN, Mahnensmith RL, Perazella MA: Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients? Am J Kidney Dis. 1997;30: 772-779.

Cayco AV, Abu-Alfa A, Mahnensmith RL, Perazella MA: "Reduction in arteriovenous graft impairment: results of a vascular access surveillance protocol. Am J Kidney Dis. 1998;32: 302-308.

Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA: Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clin Nephrol. 1998;50: 101-107.

Cruz DN, Perazella MA: Ringers Lactate: An inexpensive and effective dialysate for continuous renal replacement therapy. Am J Kidney Dis. 1999;33: 614-615.
Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA: Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. Am J Kidney Dis. 1999;33: 920-926.

Alappan R, Buller GK, Perazella MA: Trimethoprim-sulfamethoxazole therapy in outpatients: Is hyperkalemia a significant problem? Am J Nephrol. 1999;19: 389-394.

Abu-Alfa A, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ: ACE inhibitors do not induce recombinant erythropoietin resistance in hemodialysis patients. Am J Kidney Dis. 2000;35: 1076-1082.

Alappan R, Cruz D, Abu-Alfa A, Mahnensmith R, Perazella MA: Treatment of severe intradialytic hypotension with the addition of high dialysate calcium to midodrine and/or cool dialysate. Am J Kidney Dis. 2001;37: 294-299.

Perazella MA, Tray K: Selective COX-2 inhibitors: A pattern of nephrotoxicity similar to traditional NSAIDs. Am J Med. 2001;111: 64-67.

Hoeben H, Abu-Alfa AK, Mahnensmith R, Perazella MA: Hemodynamics in patients with intradialytic hypotension treated with cool dialysate or midodrine. Am J Kidney Dis. 2002;39: 102-107.

Cosgrove CJ, Abu-Alfa AK, Perazella MA: Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy (HAART). Am J Med Sci. 2002;323: 102-106.

Brewster UC, Ciampi M, Abu-Alfa AK, Perazella MA: Addition of sertraline to other therapies to reduce dialysis-associated hypotension. Nephrology 2003;8: 296-301.

Hoeben H, Abu-Alfa AK, Reilly RF, Aruny JE, Bouman K, Perazella MA: Vascular access surveillance: Evaluation of combining dynamic venous pressure and vascular access blood flow measurements. Am J Nephrol. 2003;23: 403-408.

Wood J, Mahnensmith M, Mahnensmith R, Perazella MA: Intradialytic administration of amphotericin B: clinical observations on efficacy and safety. Am J Med Sci. 2004;327: 5-8.

Brewster UC, Coca SG, Reilly RF, Perazella MA: Effect of intravenous iron on hemodialysis catheter microbial colonization and blood-borne infection. Nephrology 2005;10(2): 124-128.
Rifkin BR, Brewster UC, Aruny JE, Perazella MA: Percutaneous Balloon Cryoplasty: A New Therapy for Intractable Venous Stenosis? Am J Kidney Dis. 2005;45(2): E27-E32.

Motiwala S, Brewster UC, Perazella MA, Peixoto AJ: Reliability of a non-invasive device to measure systemic hemodynamics in hemodialysis patients. Blood Pressure Monitoring 2006;11: 33-36.

Cruz DC, Perazella MA, Bellomo R, Corradi V, de Cal M, Kuang D, Ocampo C, Nalesso F, Ronco C: Extracorporeal blood purification for prevention of radiocontrast-induced nephropathy: A systematic review. Am J Kidney Dis. 2006;48: 361-371.

Cruz DN, Bolgan I, Perazella MA, Bonello M, de Cal M, Corradi V, Polanco N, Kuang D, Ocampo C, Nalesso F, Ronco C: North East Italian Prospective Hospital Renal Outcome Survey on acute kidney injury (NEiPHROS-AKI): Targeting the problem with the RIFLE criteria. Clin J Am Soc Nephrol. 2007;2: 418-425.

Cruz DN, Perazella MA, Bellomo R, Polanco N, de Cal M, Corradi V, Nalessso F, Lentini P, Ueno T, Ranieri VM, Ronco C: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11(2): 1-12.

Seidner MA, Atta MG, Perazella MA, Lucas GM, Fine DM: Poor validity of urine dipstick as a screening tool for proteinuria in HIV patients. J Acquir Immune Defic Syndr. 2008;47(2): 261-263.

Rho M, Perazella MA, Parikh CR, Peixoto A, Brewster UC: Serum vasopressin response in patients with intradialytic hypotension: A pilot study. Clin J Am Soc Nephrol. 2008;3(3): 729-35.

Perazella MA, Coca SG, Brewster UC, Kanbay M, Parikh CR: The diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol. 2008;3(6): 1615-9.

Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, Ronco C. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med. 2010;36(3): 381-4.

Perazella MA, Coca SG, Hall IE, Iyamn U, Koraishy M, Parikh CR: Urine microscopy is associated with severity and
worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol. 2010;5(3): 402-8.

Hall IE, Coca SG, Perazella MA, Eko UU, Luciano RL, Peter PR, Han WK, Parikh CR. Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. Clin J Am Soc Nephrol. 2011;6(12): 2740-9.

Cruz DN, Goh CY, Marenzi G, Corradi V, Ronco C, Perazella MA. Renal replacement therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Med. 2012;125(1): 66-78.

Estrella MM, Jaar BG, Cavanaugh KL, Fox CH, Perazella MA, Soman SS, Howell E, Rocco MV, Choi MJ; National Kidney Foundation. Perceptions and use of the national kidney foundation KDOQI guidelines: a survey of U.S. renal healthcare providers. BMC Nephrol. 2013;14: 230.

Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, Ansari N, Coca SG, Garcia-Tsao G, Parikh CR; TRIBE-AKI Consortium. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014;60(2): 622-32.

Belcher JM, Garcia-Tsao G, Sanyal AJ, Thiessen-Philbrook H, Peixoto AJ, Perazella MA, Ansari N, Lim J, Coca SG, Parikh CR; TRIBE-AKI Consortium. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol. 2014;9(11): 1857-67

Mansour SG, Verma G, Pata RW, Martin TG, Perazella MA, Parikh CR: Kidney Injury and Repair Biomarkers in Marathon Runners. Am J Kidney Dis. 2017;70(2): 252-261.

Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of regular or extended hemodialysis and hemodiafiltration on plasma oxalate concentrations in patients with end stage renal disease. Kidney Int Reports 2017;2: 1050-1058.

Moledina DG, Luciano RL, Kukova L, Chan L, Saha A, Nadkarni G, Alfano S, Wilson FP, Perazella MA, Parikh CR. Kidney Biopsy-Related Complications in Hospitalized Patients with Acute Kidney Disease. Clin J Am Soc Nephrol. 2018; 13(11): 1633-1640.

Poloni JAT, Perazella MA, Keitel E, Marroni CA, Leite SB, Rotta LN: Utility of a urine sediment score in hyperbilirubinemia/hyperbilirubinuria. Clin Nephrol. 2019;92(3): 141-150.
Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, Obeid W, Lin H, Kuperman M, Moeckel GW, Kashgarian M, Cantley LG, Parikh CR: Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight. 2019 May 16;4(10). pii: 127456. doi: 10.1172/jci.insight.127456. eCollection 2019 May 16.

Conwell P, Aniskiewicz M, Ghidini J, DeVaux L, Perazella M, Giullian J: A Hospital-Based Program to Reduce Central Line-Associated Bloodstream Infections among Hospitalized Patients Receiving Hemodialysis Using a Central Venous Catheter for Vascular Access. Nephrol Nurs J. 2019;46(6):587-590.

Palsson R, Colona MR, Hoenig MP, Lundquist AL, Novak JE, Perazella MA, Waikar SS. Assessment of Interobserver Reliability of Nephrologist Examination of Urine Sediment. JAMA Netw Open. 2020 Aug 3;3(8):e2013959. doi: 10.1001/jamanetworkopen.2020.13959.

Moledina DG, Wilson FP, Kukova L, Obeid W, Perazella MA, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Cantley LG, Parikh CR: Urine Interleukin-9 and Tumor Necrosis Factor-α for prognosis of human acute interstitial nephritis. Nephrol Dial Transplant (in press, 2020)

2. Case Reports, Technical Notes, Letters

Buller GK, Perazella MA: Angiotensin-converting enzyme inhibitor-induced symptomatic hypoglycemia. Am J Med. 1991;91: 104.(letter)

Perazella MA, Buller GK: Hemorrhagic bursitis complicating treatment with recombinant tissue plasminogen activator (rt-PA). Am J Med. 1991;91: 440-442.

Perazella MA, Buller GK: Can ibuprofen cause acute renal failure in a normal individual? A case of acute overdose. Am J Kidney Dis. 1991;18: 600-602.

Perazella M, Brown E: Acute aluminum toxicity and alum bladder irrigation in patients with renal failure. Am J Kidney Dis. 1993;21: 44-46.

Perazella M, Eisen T, Brown E: Peritonitis associated with disseminated mycobacterium avium complex in an AIDS patient on CAPD. Am J Kidney Dis. 1993;21: 319-321.
Perazella MA, Buller GK: NSAID nephrotoxicity revisited: parenteral ketorolac induced acute renal failure. South Med J. 1993;86: 1421-1424.

Perazella MA, Eisen RN, Frederick WG and Brown E: Renal failure and severe hypokalemia associated with acute myelomonocytic leukemia. Am J Kidney Dis. 1993;22: 462-467.

Perazella MA, Magaldi J: Retinopathy in leukemia. N Engl J Med. 1994;331: 922.

Perazella MA, Sadigh M: Acute non-specific illness in an AIDS patient with dysphagia. Hosp Practice 1994;29: 39-47.

Perazella MA, Buller GK: Nephrotic syndrome associated with agnogenic myeloid metaplasia. Am J Nephrol. 1994;14: 223-225.

Velazquez H, Ellison DH, Perazella MA: Urea excretion rate as a contributor to trimethoprim-induced hyperkalemia. Ann Intern Med. 1994;120: 166.(letter)

Filatov V, Alexandrakis G, Rainey PM, Perazella MA, Gloor P: No detectable systemic absorption of topically administered ophthalmic tobramycin. Am J Ophthalm 1994;117: 402-403.

Perazella MA: Single voided urine protein/creatinine ratio. Mayo Clin Proc. 1995;70: 308-309.(letter)

Perazella MA: Abdominal pain, hypertension and renal failure. J Musculoskeletal Med. 1995;12: 69-70.

Buller GK, Perazella MA: Treatment of cystinuria with captopril. Am J Kidney Dis. 1995;25: 661-662.

Sander S, Buller GK, Perazella MA: Hypercalcemia, sarcoidosis and normal chest radiographs. Am J Med. 1995;99: 437-438.

Perazella MA: Reduction in recombinant human Erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26: 1000-1001.

Holmboe ES, Langsford C, Perazella MA: Severe hepatitis as an unusual presentation of metastatic melanoma. Connecticut Med. 1995;59: 589-592.

Perazella MA, Frederick WG, Buller GK, Widman S: Mechanical mitral valve prosthesis dysfunction from thrombus: TEE has limitations. Connecticut Med. 1996;60: 75-77.

Perazella MA: Nitric oxide and hemodialysis-induced hypotension. Ann Intern Med. 1996;124: 454. (letter)
Perazella MA: Hepatic, portal, and splenic vein gas. Consultant 1996;36: 1091-1092.

Cruz DN, Perazella MA, Mahnensmith RL: A middle-aged woman with back and flank pain. Hosp Practice 1996;31: 193-209.

Perazella MA, Alappan R, Buller GK: Hyperkalemia and trimethoprim-sulfamethoxazole. Ann Intern Med. 1996;125: 779-780. (letter)

Perazella MA, Mahnensmith RL: Dysuria in an elderly man with cardiomyopathy. Hosp Practice 1997;32: 147-154.

Cruz DM, Perazella MA: Biochemical aberrations in a dialysis patient following parathyroidectomy. Am J Kidney Dis. 1997;29: 759-762.

Perazella MA: Comparison of oral agents for treatment of Pneumocystis carinii pneumonia. Ann Intern Med. 1997;126: 407. (letter)

Buller GK, Perazella MA: Acute renal failure and ketorolac. Ann Intern Med. 1997;127: 493. (letter)

Cruz DN, Perazella MA: Hungry bone syndrome after surgical parathyroidectomy. Am J Kidney Dis. 1997;30: 730-731. (letter)

Perazella MA: A boy with headache, fatigue, and weakness. Hosp Practice 1998;33: 193-198.

Formica R, Perazella MA: Leg pain and swelling in an HIV-infected drug abuser. Hosp Practice 1998;33: 195-197.

Perazella MA, Cooney E, Kashgarian M: Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol. 1998;50: 194-196.

Perazella MA, Mahnensmith RL: Malignant hypertension. (Clinical Image in Medicine) N Engl J Med. 1998;339: 1985.

Perazella MA, Biswas P: Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis. 1999;33: 782-785.

Orias M, Mahnensmith RL, Perazella MA: Extreme hyperphosphatemia and acute renal failure after a phosphorus-containing bowel regimen. Am J Nephrol. 1999;19: 60-63.

Perazella MA, Eras J: Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis. 2000;35: 937-940.

Reilly R, Tray K, Perazella MA: Indinavir nephropathy
revisited: A pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis. 2001;38: E23-28.

Abu-Alfa AK, Perazella MA: Angiotensin-converting enzyme inhibitors and anemia in chronic kidney disease: a complex interaction. Am J Kidney Dis. 2001;39: 896-897. (letter)

Lockridge L, Papac RJ, Perazella MA: Pamidronate-associated nephrotoxicity in a patient with Langerhan’s Histiocytosis. Am J Kidney Dis. 2002;39: E2-E4.

Perazella MA: Drug-induced hyperkalemia. Am J Med. 2002;112: 334-335.

Perazella MA: A 58-year-old man with diabetes mellitus and nephrotic syndrome. Hosp Physician 2002;38: 39-42.

Coca S, Perazella MA: Acute renal failure associated with tenofovir: Evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324: 342-344.

Brewster UC, Perazella MA: Acute tubulointerstitial nephritis associated with celecoxib. Nephrol Dial Transplant. 2004;19: 1017-1018.

Brewster UC, Perazella MA: A young man with HIV infection and acute renal failure. Hosp Physician 2004;46: 37-41.

Rifkin B, Perazella MA: Tenofovir-associated nephrotoxicity: Fanconi syndrome and acute renal failure. Am J Med. 2004;117: 282-284.

Brewster UC, Perazella MA: Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis. 2004;44: E81-E84.

Brewster UC, Perazella MA: Calcific uremic arteriolopathy in a transplanted kidney. Am J Med Sci. 2005;329: 102-103.

Brewster UC, Mojiban HR, Aruny JE, Perazella MA: Complications of Central Venous Stent Placement. Am J Kidney Dis 2006;47(3): e35-6.

Stein J, Brewster UC, Perazella MA: Retroperitoneal bleed from acquired renal cysts. Seminars Dialysis 2006;19: 256.

Aruny JE, Perazella MA: An Odd Case of Hypertension. Am J Med. 2006;119: 748-750.

Singh A, Sarkar SR, Gaber LW, Perazella MA: Acute oxalate nephropathy associated with orlistat, a gastrointestinal inhibitor. Am J Kidney Dis. 2007;49: 153-157.
Brewster UC, **Perazella MA**: Acute kidney injury following proton pump inhibitor therapy. Kidney Int. 2007;71: 589-593.

Coca SG, **Perazella MA**: Prevention of contrast-induced nephropathy in high-risk patients with hemofiltration. Am J Med. 2007;120(8): e9

Vaidya C, Brewster UC, **Perazella MA**: Cachexia in a 53-year-old end-stage renal disease patient on hemodialysis. Semin Dialysis 2007;20(5): 475-6.

Singanamala S, Roer DA, **Perazella MA**: An Unexpected Finding on Chest Roentgenogram Following Hemodialysis Catheter Placement. Semin Dialysis 2008;21(3): 293-4.

**Perazella MA**, Rodby RA: Gadolinium-induced Nephrogenic Systemic Fibrosis in Patients with Kidney and Liver Disease. Am J Med. 2008;121(1): e13.

Rifkin BS, Brewster UC, **Perazella MA**: A Dialysis Patient with Apparent Air in the Biliary Tree. Semin Dial. 2008;21(6): 584-5.

**Perazella MA**, Rho M, Brewster UC. Vasopressin insufficiency and intradialytic hypotension. Am J Kidney Dis. 2008;52(6): 1197.

Kadiyala D, Roer D, **Perazella MA**: Nephrogenic systemic fibrosis associated with gadoversetamide exposure: Treatment with sodium thiosulfate. Am J Kidney Dis. 2009;53: 133-7.

Knauf F, Desir G, **Perazella MA**: A case of severe hemodynamic lability and hypocalcemia. Am J Medical Sci. 2009;338(3): 241-4.

Adebamiro A, **Perazella MA**: Recurrent acute kidney injury following bath salts intoxication. Am J Kidney Dis. 2012;59(2): 273-5.

**Perazella MA**: Drug use in the ICU. Kidney Int. 2012;82: 936-7.

Khan U, Razdan R, **Perazella MA**: Anuric acute kidney injury in neurofibromatosis 1. Am J Kidney Dis. 2013;61(3): 519-22

Vichot AA, Geller DS, **Perazella MA**: Progression of polycystic kidney disease in a kidney transplant. Kidney Int. 2013;83(3): 533.

Luciano RL, Moeckel G, Palmer M, **Perazella MA**: Babesiosis-Induced Acute Kidney Injury With Prominent Urinary Macrophages. Am J Kidney Dis. 2013;62(4): 801-805
Luciano RL, Castano E, Moeckel G, Perazella MA. Bile Acid nephropathy in a bodybuilder abusing an anabolic androgenic steroid. Am J Kidney Dis. 2014;64(3): 473-6.

Luciano RL, Castano E, Fogazzi GB, Perazella MA. Light chain crystalline kidney disease: diagnostic urine microscopy as the "liquid kidney biopsy". Clin Nephrol. 2014;82(12): 387-91.

Shirali AC, Perazella MA, Gettinger S: Association of acute interstitial nephritis with Programmed Cell Death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016;68(2): 287-91.

Porta C, Cosmai L, Gallieni M, Perazella MA. Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. J Clin Oncol. 2016;34(20): 2429-30

Rosner MH, Perazella MA: Acute Kidney Injury in Patients with Cancer. N Engl J Med. 2017;377(5): 500-501.

Sury K, Mutter M, Moeckel GS, Perazella MA: Severe orthostatic hypotension complicating multiple myeloma. J Onco-Nephrol 2017;1(3): e8-e12.

Sitkin NA, Bernstein E, Perazella MA. Atypical case of classical polyarteritis nodosa: alveolar hemorrhage and positive antineutrophil cytoplasmic antibody. Clin Nephrol. 2018;89(1): 61-66.

Jhaveri KD, Perazella MA. Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(12): 1163.

Cavanaugh C, Perazella MA: Telavancin associated acute kidney injury. Clin Nephrol. 2019;91(3): 187-191.

Sprangers B, Jhaveri KD, Perazella MA: Cancer Survivorship. N Engl J Med. 2019;380(14): 1381-1382.

Soto K, Campos P, Manso R, Antunes AMM, Morello J, Perazella MA: Severe Acute Kidney Injury and Double Tubulopathy Due to Dual Toxicity Caused by Combination Antiretroviral Therapy. Kidney Int Rep. 2018;4(3): 494-499.

Perazella MA: Acute Kidney Injury Related to Sepsis. JAMA. 2019;321(18): 1828.

Perazella MA, Weinreb JC, Davenport MS: In Reply to 'Contrast-Enhanced CT in Patients With Kidney Disease: Some
Considerations in Response to the ACR/NKF Consensus'.
Kidney Med. 2020;2(4):501.

3. Reviews, Chapters, Books

Buller GK, Perazella MA: What are the important metabolic considerations in the treatment of hypertension. Choices in Cardiology 1992;6: 1-4.

Perazella MA, Buller GK: The multiple cholesterol emboli syndrome. Res Staff Phys. 1992;38: 95-99.

Perazella MA, Bia MJ: Post transplant erythrocytosis: case report and review of newer treatment modalities. J Am Soc Nephrol. 1993;3: 1653-1659.

Perazella MA, Brown E: Electrolyte and acid-base disorders associated with AIDS: an etiologic review. J Gen Intern Med. 1994;9: 232-236.

Lee-Chiong TL, Horowitz BL, Perazella MA, Brackett JW: Thoracic actinomycosis: Forgotten but not gone. J Resp Dis. 1994;15: 1062-1072.

Smith JD, Perazella MA, DeFronzo RA: Hypokalemia: Clinical Disorders In: Arief AA, DeFronzo RA, eds. Fluid, electrolyte and acid-base disorders. 2nd Edition. pp 387-426, 1995.

Perazella MA, Mahnensmith RL: Trimethoprim-sulfamethoxazole: Hyperkalemia is an important complication regardless of dose. Clin Nephrol. 1996;46: 187-192.

Perazella MA: Hyperkalemia in the elderly: A group at high risk. Connecticut Med. 1996;60: 195-198.

Perazella MA: Lead and the kidney: Nephropathy, hypertension, and gout. Connecticut Med. 1996;60: 521-526.

Cruz DM, Perazella MA: Acute renal failure after cardiac transplantation: Case report and review of the literature. Yale J Biol Med. 1996;69: 461-468.

Cruz DN, Perazella MA: Hypertension and hypokalemia: Unusual syndromes. Connecticut Med. 1997;61: 67-75.

Perazella MA: Hyperkalemia in the elderly. Clin Geriatrics 1997;5: 78-106.

Cruz DN, Perazella MA, Mahnensmith RL: Bone marrow transplant (BMT) nephropathy: Case report and review of the literature. J Am Soc Nephrol. 1997;8: 166-173.
Perazella MA, Buller GK: Hyperkalemia and trimethoprim-sulfamethoxazole. Am J Kidney Dis. 1997;29: 959-965.

Perazella MA: Hyperkalemia and trimethoprim-sulfamethoxazole: A new problem emerges 25 years later. Connecticut Med. 1997;61: 451-458.

Perazella MA, Mahnensmith RL: Hyperkalemia in the elderly: Drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12: 246-256.

Cayco AV, Perazella MA, Hayslett JP: Renal insufficiency following intravenous immune globulin therapy: a report of two cases and analysis of the literature. J Am Soc Nephrol. 1997;8: 1788-1794.

Perazella MA: Trimethoprim is a potassium-sparing diuretic like amiloride and causes hyperkalemia in high risk patients. Am J Therapeutics 1997;4: 343-348.

Perazella MA: Midodrine: A new therapy for intradialytic hypotension. Seminars Dialysis 1997;10: 245-247.

Cruz DN, Perazella MA: Drug-induced acute tubulointerstitial nephritis: The clinical spectrum. Hosp Practice 1998;33: 151-164.

Perazella MA, Cayco AV: Acute renal failure and intravenous immune globulin: Sucrose nephropathy in disguise? Am J Therapeutics 1998;5: 399-403.

Cruz DN, Perazella MA: Chemical ablation of parathyroid hyperplasia for recurrent secondary hyperparathyroidism in an autograft. Seminars Dialysis 1998;11: 249-252.

Perazella MA: Crystal-induced acute renal failure. Am J Med. 1999;106: 459-465.

Perazella MA: Hyperkalemia in the End Stage Renal Disease patient in the emergency department. Connecticut Med. 1999;63: 131-136.

Perazella MA: Approach to patients with intradialytic hypotension: A focus on therapeutic options. Seminars Dialysis 1999;12: 175-181.

Perazella MA: Trimethoprim-induced hyperkalemia: Review of clinical data, mechanism of action, prevention and management. Drug Safety 2000;22: 227-236.

Perazella MA: HIV-associated crystal nephropathy. Res & Staff Physician 2000;46: 24-34.
**Perazella MA**: Acute renal failure in HIV-infected patients: A brief review of some common causes. Am J Med Sci. 2000;319: 385–91.

**Perazella MA**: Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med. 2000;109: 307–314.

**Perazella MA, Rastegar A**: Disorders of potassium and acid-base metabolism in association with renal disease In: Schrier RW, ed. 7th and 8th editions, 2001, ). pp. 2577-2605 2001 7th Edition.

Eras J, **Perazella MA**: NSAIDs and the kidney revisited: Are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci. 2001;321: 181-190.

**Perazella MA**: Acute renal failure in HIV-infected patients: A case-based review. Hosp Physician 2001;37: 30-41.

**Perazella MA**: COX-2 inhibitors and the kidney. Hosp Practice 2001;36: 43-56.

**Perazella MA**: Medical management of kidney and electrolyte disorders Book Note. (Medical Writings) Ann Intern Med. 2001;135: 392.

**Perazella MA**: Pharmacologic options available to treat symptomatic intradialytic hypotension. Am J Kidney Dis. 2001;38: S26-36.

**Perazella MA**: Disorders of potassium homeostasis: review questions. Hosp Physician 2001;37: 59-60.

Watnick S, **Perazella MA**: Cardiac troponins: Utility in renal insufficiency and end stage renal disease. Seminars Dialysis 2002;15: 401-405.

**Perazella MA**: COX-2 selective inhibitors: Analysis of the renal effects. Expert Opinion Drug Safety. 2002;1: 53-64.

**Perazella MA**: Acute renal failure: review questions. Hosp Physician 2002;38: 39-40.

**Perazella MA**: Renal Effects of COX-2 inhibitors in the at-risk patient. Clinical Geriatrics 2002;18: 7-9.

Reilly RF, **Perazella MA**: Chronic kidney disease: A new approach to an old problem. Connecticut Med. 2002;66: 579-583.

**Perazella MA**: Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension. Expert Opinion Drug Safety 2003;2: 37-47.
Perazella MA: Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity. Am J Medical Sci. 2003;325: 49-362.

Perazella MA, Setaro J: The renin-angiotensin aldosterone system: Fundamental aspects and clinical implications in renal and cardiovascular disorders. J Nucl Med. 2003;10: 184-196.

Perazella MA: Chronic Kidney Disease: The silent epidemic. Hosp Physician 2003;39: 15-17.

Perazella MA, Reilly RF: Chronic Kidney Disease: A new classification and staging system. Hosp Physician 2003;39:18-23.

Perazella MA: COX-2 inhibitor therapy: When is monitoring required? Consultant 2003;43: 706-708.

Gambaro G, Perazella MA: Adverse renal effects of antiinflammatory agents: Evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med. 2003;253: 643-652.

Brewster UC, Setaro JF, Perazella MA: The Renin-Angiotensin-Aldosterone System: Cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci. 2003;326: 15-24.

Ishibe S, Perazella MA, Reilly RF: Nephrogenic fibrosing dermopathy. Seminars Dialysis 2003;16: 276-280.

Perazella MA: Acute renal failure in AIDS: Preventable or inevitable? In: Ofudu O, ed. AIDS and the Kidney. pp.106-120, 2003 1st Edition.

Brewster UC, Perazella MA: Hematuria: review questions. Hosp Physician 2003;39: 17-18.

Brewster UC, Perazella MA: Can dual blockade of the renin-angiotensin-system reduce progression of kidney disease beyond monotherapy? Expert Opinion Drug Safety 2004;3: 9-23.

Brewster UC, Perazella MA: Intravenous iron and the risk of infection in end stage renal disease (ESRD) patients. Seminars Dialysis 2004;17:57-61.

Brewster UC, Perazella MA: Cardiorenal effects of the renin-angiotensin-aldosterone system. Hosp Physician 2004;40: 11-20.

Brewster UC, Perazella MA: A review of chronic lead intoxication: An unrecognized cause of chronic kidney disease. Am J Med Sci. 2004;327: 341-347.

Brewster UC, Perazella MA: Complicated hypertension: review questions. Hosp Physician 2004;40: 19-20.
Brewster UC, **Perazella MA**: The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease. Am J Med. 2004;116: 263-272.

Tray K, **Perazella MA**: NSAID nephrotoxicity revisited: Selective COX2 inhibitors. Consultant 2004;44: 1008-1011.

Markowitz G, **Perazella MA**: Drug-induced renal failure: Focus on tubulointerstitial disease. Clinica Chimica Acta. 2005;351: 31-47.

Brewster UC, **Perazella MA**: Early renal disease; Tips on recognition and prevention. Consultant 2004;44: 1613-1620.

Brewster UC, **Perazella MA**: The renin-angiotensin-aldosterone system in the kidney. Renin Angiotensin System in Cardiovasc Med. 2005;1(2): 6-9.

Coca SG, **Perazella MA**, Buller GK: The cardiovascular implications of hypokalemia. Am J Kidney Dis. 2005;45: 233-247.

Coca SG, **Perazella MA**: The adverse cardiorenal effects of aldosterone: Is aldosterone antagonism beneficial? Expert Rev in Cardiovasc Ther. 2005;3(3): 497-512.

**Nephrology Textbook (Co-editor):**
Reilly RF, **Perazella MA**, eds, *Nephrology in 30 Days*, McGraw-Hill, 2005 1st Edition

**Perazella MA**: Introduction to Nephrology. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 1-12, 2005 1st Edition.

**Perazella MA**: Diuretics. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 51-66, 2005 1st Edition.

**Perazella MA**: Disorders of Potassium Homeostasis. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 78-95, 2005 1st Edition.

**Perazella MA**: Acute Renal Failure. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 227-250, 2005 1st Edition.

**Perazella MA**: Chronic Kidney Disease. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 251-274, 2005 1st Edition.

Reilly RF, **Perazella MA**: Glomerular Diseases. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 275-305, 2005 1st Edition.
Perazella MA: Urinalysis. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 306-320, 2005 1st Edition.

Perazella MA: Tubulointerstitial Disease. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 306-320, 2005 1st Edition.

Rifkin BF, Perazella MA: Analgesic therapy in patients with chronic kidney disease: A case based approach. Hosp Physician 2005;41: 13-22.

Rifkin BS, Perazella MA: The 24-hour urine collection: a valuable diagnostic tool in the primary care setting. Res & Staff Physician 2005;51(6): 39-44.

Rifkin BF, Perazella MA: Review Questions: Analgesic therapy in patients with chronic kidney disease: A case based approach. Hosp Physician 2005;41(5): 13-22.

Perazella MA: Drug-induced nephropathy: an update. Expert Opin Drug Safety. 2005;4(4): 689-706.

Coca SG, Perazella MA: The role of aldosterone blockers in the management of chronic heart failure. Am J Med Sci. 2005;330: 176-183.

Perazella MA, Parikh C: Core Curriculum: Pharmacology. Am J Kidney Dis. 2005;46: 1129-1139.

Coca SG, Perazella MA: Strategies to prevent radiocontrast nephropathy: an evidence-based approach. Hosp Physician 2005;41: 29-38.

Leinau L, Perazella MA: Hip fractures in ESRD patients: Incidence, risk factors, and prevention. Seminars Dialysis 2006;19: 75-79.

Perazella MA: Recent onset of focal arteriovenous graft swelling. Seminars Dialysis 2006;19: 84-85.

Perazella MA, Rastegar A: Disorders of potassium and acid-base metabolism in association with renal disease In: Schrier RW, ed. Diseases of the Kidney. pp. 2577-2605, 2006 8th Edition.

Brewster UC, Perazella MA: An elderly man with hemoptysis and acute renal failure. Hospital Physician 2006;42: 43-47.
Perazella MA, Khan S: Increased Mortality in Chronic Kidney Disease: A Call to Action. Am J Med Sci. 2006;331: 150-153.

Yarlagadda S, Perazella MA: Acute renal failure in the hospital: diagnosis and management. Hosp Physician 2006;42: 51-58.

Zhu X, Perazella MA: Non-hematologic complications of erythropoietin therapy. Seminars Dialysis 2006;19: 279-284.

Kapoor J, Perazella MA: Management of acute decompensated heart failure. Hosp Physician 2006;42: 47-54.

Amedia CA, Perazella MA: Transition of patients from CKD to ESRD: Better practices for better outcomes. Disease Management 2006;9(6): 311-315.

Coca SG, Perazella MA: Nephrotoxicity of NSAIDS: Focus on selective COX-2 inhibitors. Progress in COX-2 inhibitor research. Nova Science Publishers, New York, pp.145-179, 2006 1st edition

Kapoor J, Perazella MA: Diagnostic and Therapeutic Approach to Acute Decompensated Heart Failure. Am J Med 2007;120: 121-127.

Perazella MA, Rodby RA: Gadolinium use in patients with kidney disease: A cause for concern. Seminars Dialysis 2007;20 (3): 179-185.

Perazella MA: Nephrogenic systemic fibrosis, kidney disease, and gadolinium: Is there a link? Clin J Am Soc Nephrol 2007;2: 200-202.

Perazella MA, Rodby RA: Nephrogenic systemic fibrosis: A devastating complication of gadolinium in patients with severe renal impairment. Vascular Disease Management 2007;4(2): 45-47.

Zhu X, Perazella MA: Anti-vascular endothelial growth factor (VEGF) therapy: A new cause of hypertension. Current Hypertension Reviews 2007;3: 149-155.

Rho M, Perazella MA: Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Current Drug Safety 2007;2: 147-154.

Zar T, Graeber C, Perazella MA: Recognition, treatment and prevention of propylene glycol toxicity. Seminars Dialysis
2007;20(3): 217–219.

**Perazella MA.** Rodby RA: Gadolinium induced nephrogenic systemic fibrosis in patients with kidney disease. Am J Med 2007;120(7): 561-562.

Reilly RF, **Perazella MA,** eds, *Lange Instant Access: Acid Base and Electrolytes,* McGraw-Hill, pp. 1-483, 2007 1st Edition

Brewster UC, **Perazella MA:** Proton pump inhibitors and the Kidney: Critical review. Clin Nephrol 2007;68(2): 65-72.

**Perazella MA:** Gadolinium-Contrast toxicity in patients with kidney disease: Nephrotoxicity and nephrogenic systemic fibrosis. Current Drug Safety 2008;3(1): 67-75.

Fine DM, **Perazella MA,** Lucas GM, Atta MG: Kidney Biopsy in HIV: Beyond HIVAN. Am J Kidney Dis 2008;51(3): 504-514.

**Perazella MA,** Reilly RF: Nephrogenic Systemic Fibrosis: Recommendations for gadolinium-based contrast use in patients with kidney disease. Seminars Dialysis 2008;21(2): 171-3.

**Perazella MA:** Tissue deposition of gadolinium and development of NSF: A convergence of factors. Seminars Dialysis 2008;21(2): 150-4.

**Perazella MA:** Nephrogenic systemic fibrosis and gadolinium-based contrast: What’s a nephrologist to do? Seminars Dialysis 2008;21(2): 121-2.

Yarlagadda S, **Perazella MA:** Drug-induced crystal nephropathy: An update. Expert Opin Drug Safety 2008;7(2): 147-58.

Fine DM, **Perazella MA,** Lucas GM, Atta MG: Renal disease in HIV infection: epidemiology, pathogenesis and management. Drugs 2008;68(7): 963-80.

Coca SG, **Perazella MA:** Early treatment of drug-induced acute interstitial nephritis with steroids following withdrawal of offending agent enhances renal recovery and reduces risk for chronic kidney disease. Nat Clin Pract Nephrol 2008;4: 298-9.

**Perazella MA:** How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease? Clin J Am Soc Nephrol 2008;3(3): 649-51.

Rajashekar A, **Perazella MA,** Crowley S. Systemic diseases with renal manifestations. Prim Care. 2008;35(2): 297-328.
Cruz DN, Perazella MA, Ronco C. The role of extracorporeal blood purification therapies in the prevention of radiocontrast-induced nephropathy. Int J Artif Organs. 2008;31(6): 515-24.

Brewster UC, Perazella MA: Proton pump inhibitors: Acute interstitial nephritis and other renal effects. In: DeBroe M, Porter G eds. Clinical Nephrotoxins—Renal Injury from Drugs and Chemicals. pp. 567-578, 2008, 3rd Edition

Perazella MA: Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf. 2008;3(1): 67-75.

Perazella MA, Markowitz GS: Bisphosphonate nephrotoxicity. Kidney Int 2008;74(11): 1385-93.

Perazella MA: NSAIDs and the kidney. In: Lerma EV, Nissenson AR, Berns JS, eds. Lange Current Series: Current Diagnosis & Treatment in Nephrology and Hypertension. pp. 138-145, 2008, 1st Edition

Perazella MA: Acute Renal Failure: Pathophysiological Principles. Vulnerability of the kidney to nephrotoxins. In: Ronco C, Bellomo R, and Kellum J, eds. Critical Care Nephrology. pp. 177-182, 2008, 2nd Edition

Cruz DN, Perazella MA: The Role of Extracorporeal Blood Purification Therapies in the Prevention of Radiocontrast-induced Nephropathy. In: Ronco C, Bellomo R, and Kellum J, eds. Critical Care Nephrology. pp. 1000-1006, 2008, 2nd Edition

Perazella MA: Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009;4(2): 461-9.

Markowitz GS, Perazella MA: Acute phosphate nephropathy. UpToDate 2009.

Gurevich F, Perazella MA: Renal effects of anti-angiogenesis therapy: Update for the internist. Am J Med 2009;122: 322-28.

Perazella MA and Parikh CR: How can urine microscopy influence the differential diagnosis of AKI? Clin J Am Soc Nephrol 2009;4: 691-3.

Perazella MA: Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 2009;4: 1275-83.
Perazella MA: Advanced kidney disease, Gadolinium and Nephrogenic Systemic Fibrosis: The perfect storm. Curr Opin Nephrol Hypertension 2009;18(6): 519-25.

Markowitz GS, Perazella MA: Acute phosphate nephropathy. Kidney Int 2009;76(10): 1027-34.

Perazella MA: Radiocontrast-induced nephropathy: An update. Minerva Urologica e Nefrologica 2009;61(3): 215-33.

Izzedine H, Harris M, Perazella MA: The nephrotoxic effects of HAART. Nature Reviews Nephrology 2009;5: 563-573.

Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A. Erythropoiesis stimulatory agent resistant anemia in dialysis patients: Review of causes and management. Blood 2009;29(1): 1-12.

Perazella MA: Nephrogenic systemic fibrosis. Renal and Urology News 2009;12: 1-2.

Kanbay M, Kasapoglu B, Perazella MA: Acute tubular necrosis and pre-renal acute kidney injury: utility of urine microscopy in their evaluation- a systematic review. Int Urol Nephrol. 2010;42(2): 425-33.

Perazella MA: Toxic nephropathies: Core Curriculum 2010. Am J Kidney Dis 2010;55: 399-409

Fine DM, Perazella MA: Nephrogenic Systemic Fibrosis: what the Hospitalist needs to know. J Hospital Med 2010;5(1): 46-50.

Perazella MA: Nephrology Fellowship Training in the 21st Century: Where do we stand? Clin J Am Soc Nephrol 2010;5(3): 387-9.

Perazella MA, Pope JE, Cowper SE: Nephrogenic Systemic Fibrosis and Other Scleroderma Mimickers. In: Stone J, ed. Clinician’s Pearls and Myths in Rheumatology pp.97-106, 2010, 2nd Edition

Markowitz GS, Perazella MA: Drug-induced acute interstitial nephritis. Nature Reviews Nephrology 2010;6(8): 461-70.

Perazella MA: Pharmacology and kidney disease: lessons learned from the gadolinium-NSF story. NephSAP 2010;9(4): 213-219.
Kalyesubula R, **Perazella MA**: HIV-related drug nephrotoxicity in sub-Saharan Africa. Internet J Nephrol 2010;6(1).

**Perazella MA**, Moeckel G: Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology and prevention/therapy. Sem Nephrol 2010;30(6): 570-81.

**Perazella MA**: Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy. Kidney Int 2010;78(11): 1060-3.

Margaryan A, **Perazella MA**, Mahnensmith RL, Abu-Alfa AK. Experience with outpatient computed tomographic-guided renal biopsy. Clin Nephrol. 2010;74(6): 440-5.

**Perazella MA**: Book Review: The urinary sediment. An integrated view. Kidney Int 2011

**Perazella MA**, Reilly RF: Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci. 2011;341(3): 215-21.

Cruz DN, **Perazella MA**: Corrigendum regarding the article by Song et al. entitled 'Renal replacement therapy for prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials'. Am J Nephrol 2011;34(2): 173

Manjunath V, **Perazella MA**: Imaging patients with kidney disease in the era of NSF: can it be done safely? Clin Nephrol 2011;75(4): 279-85.

Kalyesubula R, **Perazella MA**: Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011: 562790.

**Perazella MA**, Rodby RA: Common clinical quandaries encountered in dialysis and ESRD: questions answered. Semin Dial. 2011;24(4): 363.

Coca SG, **Perazella MA**: Radioiodine and MRI Contrast Kidney Damage. In: Daugurdas J, ed. Handbook of Chronic Kidney Disease Management. Lippincott Williams & Wilkins, pp. , 2011, 1st Edition

**Perazella MA**, Coca SG: Traditional urinary biomarkers in the assessment of hospital-acquired AKI. Clin J Am Soc Nephrol. 2012;7(1): 167-74.

**Perazella MA**: Acute kidney injury: Medications. In: Lerma EV, Nissenson AR, eds. Nephrology Secrets Elsevier.pp.78-84, 2012, 3rd edition
Brewster UC, Perazella MA: Chronic kidney disease and hemodialysis. In: McLean, Ross J, eds. The Principles and Practice of Hospital Medicine. American College of Physicians and McGraw-Hill, pp. 2077-2083, 2012, 1st edition

Perazella MA: Crystal-induced acute kidney injury. UpToDate 2012.

Santos SF, Peixoto AJ, Perazella MA: How should we manage adverse intradialytic blood pressure changes? Adv Chronic Kidney Dis. 2012;19(3): 158-65.

Perazella MA: Drug use and nephrotoxicity in the ICU. Kidney Int 2012;81(12): 1172-8.

Perazella MA: Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012; 7(10): 1713-21.

Perazella MA: AKI in a hospitalized patient with cellulitis. Clin J Am Soc Nephrol. 2013;8(4): 658-64.

Perazella MA: Proton pump inhibitors and hypomagnesemia: a rare but serious complication. Kidney Int. 2013;83(4): 553-6.

Perazella MA, Coca SG: Three feasible strategies to minimize kidney injury in ‘incipient AKI’. Nat Rev Nephrol. 2013;9(8): 484-90.

Knauf F, Chaknos CM, Berns JS, Perazella MA: Dabigatran and kidney disease: A bad combination. Clin J Am Soc Nephrol. 2013;8(9): 1591-7.

Luciano R, Perazella MA: NSAIDs: acute kidney injury. UpToDate 2013.

Nephrology Textbook (Co-editor):
Reilly RF, Perazella MA, eds, Nephrology in 30 Days, McGraw-Hill, 2013 2nd Edition

Perazella MA: Introduction to Nephrology. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 1-12, 2013 2nd Edition.

Perazella MA, Rastegar M: Diuretics. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 51-66, 2013 2nd Edition.

Perazella MA, Rastegar M: Disorders of Potassium Homeostasis. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 78-95, 2005 1st Edition.
Perazella MA, Rastegar M: Acute Kidney Injury. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 227-250, 2013 2nd Edition.

Perazella MA, Lerma EV: Chronic Kidney Disease. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 251-274, 2013 2nd Edition.

Reilly RF, Perazella MA: Glomerular Diseases. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 275-305, 2013 2nd Edition.

Perazella MA: Urinalysis. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 306-320, 2013 2nd Edition.

Perazella MA, Lerma EV: Tubulointerstitial Disease. In: Reilly RF, Perazella MA, eds Nephrology in 30 Days. pp. 306-320, 2013 2nd Edition.

Nephrology Textbook (Co-editor):
Gilbert S, Weiner D, Gibson D, Perazella MA, Tonelli M, eds, Primer on Kidney Diseases, Elsevier, 2013 6th Edition

Perazella MA, Shirali A: Kidney Disease caused by Therapeutic Agents. In: Gilbert S, Weiner D, Gibson D, Perazella MA, Tonelli M, eds, Primer on Kidney Diseases, pp. 337-346, 2013 6th Edition

Perazella MA, Bomback AS: Urinary eosinophils in AIN: Farewell to an old biomarker? Clin J Am Soc Nephrol. 2013;8(11): 1841-3.

Perazella MA, Berns JS, Rosner MH: Cancer and the kidney: the growth of onco-nephrology. Adv Chronic Kidney Dis. 2014;21(1): 4-6.

Shirali AC, Perazella MA: Tubulointerstitial injury associated with chemotherapeutic agents. Adv Chronic Kidney Dis. 2014;21(1): 56-63.

Palmer BF, Perazella MA, Choi M: American Society of Nephrology Quiz and Questionnaire 2013: Electrolyte and Acid-Base. Clin J Am Soc Nephrol. 2014;9(6): 1132-7.

Fervenza FC, Perazella MA, Choi M: American Society of Nephrology Quiz and Questionnaire 2013: Glomerulonephritis. Clin J Am Soc Nephrol. 2014;9(5): 987-96.
Kalyesubula R, Bagasha P, Perazella MA: ACE-I/ARB therapy prior to contrast exposure: what should the clinician do? Biomed Res Int. 2014;2014: 423848.

Luciano RL, Perazella MA: Nephrotoxic effects of designer drugs: synthetic is not better! Nat Rev Nephrol. 2014;10(6): 314-24.

Perazella MA: Diagnosing drug-induced AIN in the hospitalized patient: A challenge for the clinician. Clin Nephrol. 2014;81(6): 381-8.

Josephson MA, Perazella MA, Choi M: American Society of Nephrology Quiz and Questionnaire 2013: Transplantation. Clin J Am Soc Nephrol. 2014;9(7): 1319-27.

Rodby RA, Perazella MA: Common clinical quandaries encountered by nephrologists: more questions answered. Semin Dial. 2014;27(3): 221-2.

Mehrotra R, Perazella MA, Choi M: American Society of Nephrology Quiz and Questionnaire 2013: RRT. Clin J Am Soc Nephrol. 2014;9(8): 1497-1503.

Kumar N, Perazella MA: Differentiating HIV-associated Nephropathy from Antiretroviral Drug-Induced Nephropathy: A Clinical Challenge. Curr HIV/AIDS Rep. 2014;11(3): 202-11.

Perazella MA: Magnetic resonance imaging in ESRD patients: What are the options? Semin Dial. 2014;27(6): 610-13.

Perazella MA, Turner J: Acute kidney injury. In: Benjamin, Griggs, Wing & Fitz, eds Cecil Textbook of Medicine. pp. 1-11, 2014 9th Edition.

Luciano RL, Perazella MA: Crystalline-induced kidney disease: a case for urine microscopy. Clin Kidney J. 2015; 8(2): 131-6.

Luciano RL, Perazella MA: Aristolochic Acid Nephropathy: Epidemiology, clinical presentation, and treatment. Drug Safety, 2015;38(1): 55-64.

Krishnan N, Perazella MA: Drug-induced Acute Interstitial Nephritis: Pathology, Pathogenesis, and Treatment. Iran J Kidney Dis. 2015;9(1): 3-13.

Rosner MH, Perazella MA, Choi MJ: American Society of Nephrology Quiz and Questionnaire 2014: Acid-Base and Electrolyte Disorders. Clin J Am Soc Nephrol. 2015;10(3): 530-9.
Izzedine H, **Perazella MA**: Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. Nephrol Dial Transplant. 2015;30(12): 1979-88.

Bomback AS, **Perazella MA**, Choi MJ: American Society of Nephrology Quiz and Questionnaire 2014: GN. Clin J Am Soc Nephrol. 2015;10(4): 716-722

**Perazella MA**, Izzedine H: New drug toxicities in the onco-nephrology world. Kidney Int. 2015;87(5): 909-17

Gorlitsky BR, **Perazella MA**: Shocking urine. Kidney Int. 2015;87(4): 865.

Moledina DG, **Perazella MA**: Acute kidney injury and mortality in the elderly: add atypical antipsychotics to the list. M J Kidney Dis. 2015;65(5): 655-8

**Perazella MA**: Commentary. Clin Chem. 2015;61(5): 701-2.

Greenberg KI, **Perazella MA**, Atta MG. HIV and HCV Medications in End-Stage Renal Disease. Semin Dial. 2015;28(4): 397-403

Josephson MA, **Perazella MA**, Choi MJ: American Society of Nephrology Quiz and Questionnaire 2014: Transplantation. Clin J Am Soc Nephrol. 2015;10(5): 903-9

Markowitz GS, Bomback AS, **Perazella MA**: Drug-Induced Glomerular Disease: Direct Cellular Injury. Clin J Am Soc Nephrol. 2015;10(7): 1291-9

Radhakrishnan J, **Perazella MA**: Drug-Induced Glomerular Disease: Attention Required! Clin J Am Soc Nephrol. 2015;10(7): 1287-90

Mehrotra R, **Perazella MA**, Choi MJ: American Society of Nephrology Quiz and Questionnaire 2014: RRT. Clin J Am Soc Nephrol. 2015;10(6):1100-6

Izzedine H, **Perazella MA**: Thrombotic Microangiopathy, Cancer, and Cancer Drugs. Am J Kidney Dis 2015;66(5): 857-68

**Perazella MA**: The Urine Sediment as a Biomarker of Kidney Disease. Am J Kidney Dis. 2015;66(5): 748-55

**Perazella MA**, Luciano RL: Review of selected causes of drug-induced AKI. Exp Rev Clin Pharmacol 2015;8(4): 367-71.

**Perazella MA**, Izzedine H: The Authors reply. Kidney Int. 2015;88(1): 200

Jhaveri KD, **Perazella MA**: Nephrologists as Educators: Clarifying Roles, Seizing Opportunities. Clin J Am Soc
Nephrol 2016;11(1): 176-89

Cosmai L, Porta C, Gallieni M, Perazella MA: Onco-nephrology: a decalogue. Nephrol Dial Transplant. 2016; 31(4): 515-9.

Josephson MA, Perazella MA, Choi MJ: American Society of Nephrology Quiz and Questionnaire 2015: Transplantation. Clin J Am Soc Nephrol. 2016;11(6): 1114-22.

Tesser Poloni JA, Garcia CD, Rotta LN, Perazella MA: Calcium oxalate crystalluria points to primary hyperoxaluria type 1. Kidney Int. 2016;89(1): 250.

Rosner MH, Perazella MA, Choi MJ: American Society of Nephrology Quiz and Questionnaire 2015: Acid-Base and Electrolyte Disorders. Clin J Am Soc Nephrol. 2016;11(4): 735-44.

Perazella MA: The role of mast cells in AIN: friend, foe, bystander, or all of the above? Clin Nephrol. 2015;84(3): 123-6.

Bomback AS, Perazella MA, Choi MJ: American Society of Nephrology Quiz and Questionnaire 2015: GN. Clin J Am Soc Nephrol. 2016;11(5): 884-90.

Hu SL, Chang A, Perazella MA, Okusa MD, Jaimes EA, Weiss RH; American Society of Nephrology Onco-Nephrology Forum: The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol. 2016;27(8): 2227-37.

Lok CE, Perazella MA, Choi MJ: American Society of Nephrology Quiz and Questionnaire 2015: ESRD/RRT. Clin J Am Soc Nephrol. 2016;11(7): 1313-20.

Moledina DG, Perazella MA: Proton Pump Inhibitors and CKD. J Am Soc Nephrol. 2016;27(10): 2926-2928.

Moledina DG, Perazella MA: PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29(5): 611-6.

Rodby RA, Perazella MA: Mistakes We Make in Dialysis: An Introduction. Semin Dial. 2016;29(4): 257.

Perazella MA, Wilson FP: Preventing acute kidney injury through nephrotoxin management. Nat Rev Nephrol. 2016;12(9): 511-512.

Markowitz GS, Bomback AS, Perazella MA: Phosphate enemas and GFR decline: it's premature to sound the alarm. Kidney Int. 2016;90(1): 8-15.
Asch WS, Perazella MA: Cancer and mortality in solid-organ transplantation: preventable or inevitable. Am J Kidney Dis. 2016;68(6): 839-842.

Perazella MA: Checkmate: Kidney injury associated with targeted cancer immunotherapy. Kidney Int. 2016;90(3): 474-6.

Izzedine H, El-Fekih RK, Perazella MA: The renal effects of ALK inhibitors. Invest New Drugs. 2016;34(5): 643-9.

Perazella MA, Finkel KW: Paraprotein-Related Kidney Disease: Attack of the Killer M Proteins. Clin J Am Soc Nephrol. 2016;11(12): 2256-2259.

Perazella MA: Clinical Approach to Diagnosing Acute and Chronic Tubulointerstitial Disease. Adv Chronic Kidney Dis. 2017;24(2): 57-63.

Izzedine H, Perazella MA: Adverse kidney effects of epidermal growth factor receptor inhibitors. Nephrol Dial Transplant. 2017;32(7): 1089-1097.

Perazella MA: Onco-Nephrology Highlights: Renal Consults from the Oncology Floor. J Onco-Nephrol 2017;1(1): 5-8.

Perazella MA, Izzedine H: Crizotinib: Renal safety evaluation. J Onco-Nephrol 2017;1(1): 49-56.

Rosner MH, Perazella MA: Acute kidney injury in cancer patients. N Engl J Med 2017;376: 1770-81.

Krishnan N, Perazella MA: The Role of PET Scanning in the Evaluation of Patients With Kidney Disease. Adv Chronic Kidney Dis. 2017;24(3): 154-161.

Perazella MA: Diagnostic Testing in AKI: Let's Move the Field Forward. J Hosp Med. 2017;12(5): 380-381.

Perazella MA: Onco-Nephrology Highlights: Growth of the kidney-cancer connection. J Onco-Nephrol 2017;1(1): 5-8.

Izzedine H, Perazella MA: Anti-cancer drug-induced acute kidney injury. Kidney Int Reports 2017;2(4): 504-514.

Tesser Poloni JA, Perazella MA: A rarely recognized cause of AKI in rhabdomyolysis. Am J Med Sci. 2018;356(3): e27.

Saly DL, Perazella MA: Harnessing basic and clinic tools to evaluate SGLT2 inhibitor nephrotoxicity. Am J Physiol Renal Physiol. 2017;313(4): F951-F954.
Rosner MH, Capasso G, Perazella MA: Acute kidney injury and electrolyte disorders in the critically ill patient with cancer. Curr Opin Crit Care. 2017;23(6): 475-483.

Moledina DG, Perazella MA: Drug-Induced Acute Interstitial Nephritis. Clin J Am Soc Nephrol. 2017;7;12(12): 2046-2049.

Shah M, Perazella MA: AKI in multiple myeloma: Paraproteins, metabolic disturbances, and drug toxicity. J Onco-Nephrol. 2017;1(3): 188-197.

Perazella MA: Update on the renal effects of anticancer agents. J Onco-Nephrol. 2017;1(3): 170-178.

Perazella MA: New horizons in nephrology: update in onco-nephrology. J Onco-Nephrol. 2017;1(3): 147-150.

Nussbaum EZ, Perazella MA: Update on the nephrotoxicity of novel anticancer agents. Clin Nephrol. 2018;89(3): 149-165.

Poloni JAT, de Moraes Sassi MG, de Oliveira TF, Rotta LN, Perazella MA: Blue-green discoloration of urine and false nephrotic range proteinuria at dipstick urinalysis. Clin Chim Acta. 2018;482: 74-77.

Nolin TD, Perazella MA: Introduction to Nephropharmacology for the Clinician: A New CJASN Series. Clin J Am Soc Nephrol. 2018;13(7): 1083-84.

Perazella MA, Dreicer R, Rosner MH: Renal cell carcinoma for the nephrologist. Kidney Int. 2018;94(3): 471-483.

Perazella MA, Dreicer R, Rosner MH. The authors reply. Kidney Int. 2018; 94(6):1238-1239.

Perazella MA: Pharmacology behind common drug nephrotoxicities. Clin J Am Soc Nephrol. 2018;13(12): 1897-1908.

Perazella MA, Shirali AC: Nephrotoxicity of cancer immunotherapies: Past, present and future. J Am Soc Nephrol. 2018;29(8): 2039-2052.

Perazella MA, Rosner MH: Acute kidney injury in patients with cancer. Oncology 2018;32(7): 351-9.

Cosmai L, Porta C, Perazella MA, Launay-Vacher V, Rosner MH, Jhaveri KD, Floris M, Pani A, Teuma C, Szczylk CA, Gallieni M. Opening an onconephrology clinic: recommendations and basic requirements. Nephrol Dial Transplant. 2018;33(9): 1503-1510.
Sury K, Perazella MA, Shirali AC: Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol. 2018;14(9): 571-588.

Cavanaugh C, Perazella MA: Urine Sediment Examination in the Diagnosis and Management of Kidney Disease: Core Curriculum 2019. Am J Kidney Dis. 2018;73(2): 258-272.

Moledina DG, Perazella MA: Treatment of drug-induced acute tubulointerstitial nephritis: The search for better evidence. Clin J Am Soc Nephrol 2018;13(12): 1785-1787.

Saly DL, Perazella MA: The adverse kidney effects of cancer immunotherapies. J Onco-Nephrol 2018;2(2): 56-68.

Abudayyeh A, Perazella MA: Onconephrology: Kidney disease in cancer patients. In: Feehally, Floege, Johnson and Tonelli, eds, Comprehensive Clinical Nephrology, pp 776-785, 2018 6th Edition.

Tucker BM, Perazella MA. Pink Urine Syndrome: A Combination of Insulin Resistance and Propofol. Kidney Int Rep. 2018; 4(1): 30–39.

Shah HH, Uppal NN, Perazella MA. Cancer Drugs and the Glomerulus. J Onco-Nephrol. 2018;2(2): 92–101

Perazella MA, Sprangers B: AKI in Patients Receiving Immune Checkpoint Inhibitors. Clin J Am Soc Nephrol. 2019; 14(7): 1077-1079.

Sury K, Perazella MA: The nephrotoxicity of new immunotherapies. Expert Rev Clin Pharmacol. 2019; 12(6): 513-521.

Perazella MA: Acute Kidney Injury Related to Sepsis. JAMA. 2019;321(18): 1828.

Sury K, Perazella MA: The Changing Face of Human Immunodeficiency Virus-Mediated Kidney Disease. Adv Chronic Kidney Dis. 2019;26(3): 185-197.

Saly DL, Perazella MA: Adverse Kidney Effects of Immunotherapies. In: Finkel K, Cohen E, Perazella MA, eds, Onco-Nephrology, pp. , 2019 1st Edition

Rosner MH, Perazella MA: Acute kidney injury in the patient with cancer. Kidney Res Clin Pract. 2019;38(3): 295-308.
Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, Ronco P, Rosner MH, Trepiccione F, Viggiano D, Zoccali C, Capasso G; International Conference on Onco-Nephrology Participants: Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney Int. 2019;96(3): 555-567.

**Perazella MA:** Drug-induced acute kidney injury: diverse mechanisms of tubular injury. Curr Opin Crit Care. 2019;25(6): 550-557.

Rosner MH, **Perazella MA:** Onconephrology: Kidney Disease and Cancer. In: Yu A, Skorecki, Chertow G, Marsden P, Taal M, Luyckx V, eds, *Brenner and Rector’s The Kidney*, pp , 2019 11th Edition.

**Perazella MA**, Rosner MH: Tubulointerstitial Diseases. In: Yu A, Skorecki, Chertow G, Marsden P, Taal M, Luyckx V, eds, *Brenner and Rector Nephrology*, pp , 2019 11th Edition.

Nolin TD, **Perazella MA:** Drug-induced kidney disease. In: DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, and Ellingrod V, eds, *Pharmacotherapy: a Pathophysiologic Approach*, pp. 2020 11th Edition

Rodby R, **Perazella MA**, Berns JS. The changing of the guard. Semin Dial. 2019;32(6): 482-484.

**Perazella MA**, Shirali AC: Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 2020;97(1):62-74.

Sprangers B, Jhaveri KD, **Perazella MA:** Improving Cancer Care for Patients With Chronic Kidney Disease. J Clin Oncol. 2020;38(3):188-192.

Renaghan AD, Jaimes EA, Malyszko J, **Perazella MA**, Sprangers B, Rosner MH: Acute Kidney Injury and CKD associated with Hematopoietic Stem Cell Transplantation. Clin J Am Soc Nephrol. 2020;15(2):289-297.

Davenport MS, **Perazella MA**, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020; 294(3):660-668.
**Perazella MA**, Turner J: Acute kidney injury. In: Benjamin, Griggs, Wing & Fitz, eds Cecil Textbook of Medicine. pp. 1-11, 2020 10th Edition.

**Perazella MA**: Is urine microscopy a useful early biomarker for cardiac surgery related AKI? J Bras Nefrol. 2020;42(1):1-3.

Baker ML, **Perazella MA**: SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? J Nephrol. 2020 Feb 18. doi: 10.1007/s40620-020-00712-5. Online ahead of print. PMID: 32067179

Baker M, **Perazella MA**: NSAIDs in CKD: Are They Safe? Am J Kidney Dis. 2020 May 29:S0272-6386(20)30724-1. doi: 10.1053/j.ajkd.2020.03.023. Online ahead of print. PMID: 32479922

Izzedine H, Jhaveri KD, **Perazella MA**: Vascular injury and COVID-19-related mortality: What lies below the tip of the iceberg? Clin Nephrol. 2020;94(1):11-13.

Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehtrotra R, Palevsky PM, **Perazella MA**, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC: Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020 Jun;97(6):1117-1129.

Sprangers B, Abudayyeh A, Latcha S, **Perazella MA**, Jhaveri KD: How to determine kidney function in cancer patients? Eur J Cancer. 2020;132:141-149.

Izzedine H, Jhaveri KD, **Perazella MA**: COVID-19 therapeutic options for patients with kidney disease. Kidney Int. 2020;97(6):1297-1298.

Herrmann SM, **Perazella MA**: Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Reports 2020;5:1139–1148
Perazella MA, Nolin TD: Adverse drug effects in patients with CKD – Primum Non Nocere. Clin J Am Soc Nephrol. 2020; 15 (8) 1075-1077.

Rosner MH, Jhaveri KD, McMahon BA, Perazella MA: Onconephrology: The Intersections between the Kidney and Cancer. CA: Cancer J Clin. 2020 Aug 27. doi: 10.3322/caac.21636.

Kramer H, Joseph J, Rosner MH, Perazella MA: In Case of a Pandemic, Pivot: Moving the National Kidney Foundation Spring Clinical Meetings Online. Am J Kidney Dis. 2020; Sep 22:S0272-6386(20)31000-3. doi: 10.1053/j.ajkd.2020.09.004.